Santarus, Inc. (SNTS)
-NasdaqGS 21.91 
0.64(3.01%) May 17, 4:00PM EDT|After Hours
:
21.94 0.03 (0.14%) May 17, 4:43PM EDT
| Prev Close: | 21.27 |
|---|
| Open: | 21.46 |
|---|
| Bid: | 18.12 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 22.30 |
|---|
| Beta: | 1.8 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 21.28 - 21.97 |
|---|
| 52wk Range: | 4.82 - 21.97 |
|---|
| Volume: | 1,054,755 |
|---|
| Avg Vol (3m): | 1,256,070 |
|---|
| Market Cap: | 1.42B |
|---|
| P/E (ttm): | 42.46 |
|---|
| EPS (ttm): | 0.52 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- IBD 50 Stocks Delivering Strong Earnings, Sales Gainsat Investor's Business Daily(Fri, May 17)
- Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week MeetingBusiness Wire(Fri, May 17)
- Santarus' CEO Presents at Bank of America/Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Thu, May 16)
- Pharming reports on financial results first quarter 2013Thomson Reuters ONE(Thu, May 16)
- Good News for Novartis' IlarisZacks(Wed, May 15)
- Santarus Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock OfferingBusiness Wire(Wed, May 15)
- Pediatric Approval for MDCO/BMY's RecothromZacks(Wed, May 15)
- 'Superperformance' Stocks Mid-May Updateat Seeking Alpha(Wed, May 15)
- Synergy Pharma Posts Wider LossZacks(Wed, May 15)
- Dr. Reddy's Earnings Increase Y/YZacks(Wed, May 15)
- Special Dividend and Ongoing Cash Distributionat Motley Fool(Tue, May 14)
- 2 Biotech Companies With Strong Product Launches To Monitorat Seeking Alpha(Tue, May 14)
- Forest-Trevena Ink DealZacks(Tue, May 14)
- Jazz Pharma Posts Higher Y/Y EarningsZacks(Tue, May 14)
- Salix Beats on EarningsZacks(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | 16.98 |
|---|
| P/S (ttm): | 5.49 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.88 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.17 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | 1.18 |
|---|
Business Summary
Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists.
View More